Table 1.
Formulation differences between licensed pneumococcal vaccines currently in use.
| PCV10 | PCV13 | PPV23 | |
| Valency | 10-valent | 13-valent | 23-valent |
| Serotypes included | 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F | 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F | 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F |
| Type | Conjugated PS | Conjugated PS | Plain PS |
| Carrier protein (s) | TT with serotype 18C, DT with 19F, PD with all other serotypes | CRM with each serotype | none |
| Polysaccharide amount | 1 μg/serotype (*3 μg/serotype for 4, 18C, 19F) | 2.2 μg/serotype (*4.4 μg/serotype for 6B) | 25 μg/serotype |
| Administration route | IM | IM | IM |
| Target population | healthy children | healthy children and adults >50 years of age | at risk population >2 years of age and adults >65 years of age |
PCV10: 10-valent pneumococcal conjugate vaccine; PCV13: 13-valent pneumococcal conjugate vaccine; PPV23: 23-valent plain polysaccharide pneumococcal vaccine; PS: polysaccharide; PD: protein D from non-typeable Haemophilus influenzae; TT: Tetanus Toxoid; DT: Diphtheria Toxoid; CRM: CRM197 a non-toxic mutant of the diphtheria toxin; PCV7: 7-valent pneumococcal conjugate vaccine; IM: intramuscular.